Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 2/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937701 | 0.80 | CDK5 (0.39) | MAPK1CDK5CDK5R1KCNH2KMT2A | |
| SCHEMBL30937521 | 0.80 | CDK5 (0.39) | MAPK1CDK5CDK5R1KCNH2KMT2A | |
| SCHEMBL8134588 | 0.79 | BRD4 (0.66) | CDK5CDK5R1BRD4KCNH2 | |
| SCHEMBL828518 | 0.77 | BRD4 (0.61) | MAPK1CDK5CDK5R1BRD4XIAP | |
| SCHEMBL30937529 | 0.76 | MAPK1 (0.38) | MAPK1CDK5CDK5R1BRD4KMT2A | |
| SCHEMBL30912755 | 0.76 | HTR5A (0.46) | MAPK1CDK5CDK5R1BRD4HTR5A | |
| SCHEMBL18086763 | 0.74 | KCNH2 (0.57) | KCNH2DPP4DPP8DPP9DPP7 | |
| SCHEMBL29546920 | 0.74 | P2RX7 (0.47) | MAPK1CDK5CDK5R1BRD4KCNH2 | |
| SCHEMBL29546585 | 0.73 | CDK5 (0.49) | CDK5CDK5R1BRD4HTR5A | |
| SCHEMBL29546888 | 0.72 | CDK5 (0.51) | CDK5CDK5R1BRD4KCNH2HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | MAPK1 3854/4885CDK5 857/4885CDK5R1 2238/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MAPK1 3854/4885CDK5 857/4885CDK5R1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.